|
WO2008157003A2
|
|
Chemical inhibitors of bfl-1 and related methods
|
|
JP2008253257A
|
|
Nucleic acid encoding acetyl coenzyme a transporter protein
|
|
US2008182328A1
|
|
Mammalian extraembryonic endoderm cells and methods of isolation
|
|
US2009043099A1
|
|
Methods and compositions for derepression of IAP-inhibited caspase
|
|
CA2662684A1
|
|
High affinity ephb receptor binding compounds and methods of use thereof
|
|
US2009049046A1
|
|
Annotation and publication framework
|
|
AU2007202996A1
|
|
Methods and compositions for derepression of IAP-inhibited caspase
|
|
US7465585B1
|
|
Compositions and methods for inhibiting cell migration
|
|
EP1993583A2
|
|
Inhibitors of membrane type-1 matrix metalloproteinase for the treatment of insulin-dependent diabetes mellitus
|
|
US2006275876A1
|
|
Use of selective labeling to detect and characterize molecular interactions by nuclear magnetic resonance spectroscopy
|
|
WO2006124537A1
|
|
Compounds that regulate apoptosis
|
|
WO2006102068A2
|
|
Methods and compositions for derepression of iap-inhibited caspase
|
|
US2011183358A1
|
|
Methods and compositions for derepression of iap-inhibited caspase
|
|
CN101146822A
|
|
EphB receptor-binding peptides
|
|
WO2006047162A2
|
|
Compositions and methods for treatment of disease caused by yersinia spp infection
|
|
WO2006036928A2
|
|
Inhibitors of matrix metalloproteinases to treat neurological disorders
|
|
WO2006029343A2
|
|
Peptides that selectively home to heart vasculature and related conjugates and methods
|
|
WO2006010146A2
|
|
Functional variant of lymphoid tyrosine phosphatase is associated with autoimmune disorders
|
|
WO2006004622A2
|
|
Inhibition of bid-induced cell-death using small organic molecules
|
|
US2005276818A1
|
|
Uncharacterized ORF3 in SARS-coronavirus is a cyclic-AMP-dependent kinase and a target for SARS therapy
|
